Friday, July 27, 2018

2:00 PM - 3:30 PM

Maritime Room 4

---

Details

How we treat Type 2 diabetes is rapidly changing. A number of new medicines and new classes have come onto the market over the past few years, and keeping up with these advancements can be a challenge. This session will focus on a number of new classes for the treatment of Type 2 diabetes, including DDP4 (dipeptidyl peptidase-4) inhibitors, SGLT2 (sodium-glucose co-transporter 2) inhibitors and GLP1 (glucagon-like peptide-1) receptor agonists. Their pharmacology, advantages and disadvantages will be discussed, particularly new data suggesting additional cardiovascular benefits with SGLT2 inhibitors and GLP1 agonists, providing you with an understanding of how these treatments can fit into your patients’ treatment regimens, including the enhanced role in cardiovascular disease. Learning objectives: • Describe the pathophysiology of Type 2 diabetes • Explain the pharmacology of DPP4 inhibitors, SGLT2 inhibitors and GLP1 receptor agonists • Explain their place in the treatment paradigm for Type 2 diabetes • Discuss the role and evidence to support SGLT-2 inhibitors and GLP1 agonists in reducing cardiovascular death and improving outcomes • Analyse the appropriateness of their use in conjunction with other medicines and comorbidities Competency Standards: • 2016: 3.1.2, 3.2.3, 3.3.2 • 2010: 4.2.2, 6.1.2, 7.1.2, 7.1.3

---

Speaker